LabCorp Drug Development, Charles River and Eurofins Scientific are dominating the North America Medicinal Chemistry for Drug Discovery Market 2021

North America Medicinal Chemistry for Drug Discovery Market is expected to grow with the CAGR of 14.0% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @

North America medicinal chemistry for drug discovery market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in North America medicinal chemistry for drug discovery market are introducing strong range of services portfolio. This helped companies to maximize the sales with enhanced services portfolio.

For instance,

  • In October 2020, Lonza unveiled its latest PyroCell MAT System to detect various pyrogens sensitively and sustainably, without the need for laboratory animals. The product was launched with a full solution with optimized MAT reagents from Sanquin and media and accessories from Lonza. The company's introduction of this new product has boosted its credibility and market demand.

Labcorp Drug Development, is dominating player in North America Medicinal Chemistry for drug discovery market. The other key players existing in the market includes Eurofins Scientific, Charles River, Wuxi Apptec, Evotec SE, Priamal Pharma Solutions, Thermo Fisher Scientific Inc., Aurigene Pharmaceuticals Services, Aurelia Bioscience, BioBlocks Inc., Certara Inc., Drug Discovery Alliances, Genscript Biotech, Jubilant Biosys, Nanosyn, Nereid Therapeutics, Pfizer Inc., Selvita, Spectris PLC, Sygnature Discovery and Taros Chemical GMBH among others.

North America Medicinal Chemistry for Drug Discovery MarketEUROFINS SCIENTIFIC

Eurofins Scientific has headquartered in Luxembourg, Germany was founded in 1987. The company is engaged in the developments of Agro testings, Bio Pharma, Cosmetics and Personal care, Food and Feed testing and Forensic science. They combine insights from multiple data sources to drive more effective and efficient research and allow for better therapeutic decisions for patients.

  • In February 2020, Eurofins acquired Beacon Discovery for its innovative approach, years of experience in drug discovery and development, and profound expertise in GPCR (G-Protein Coupled Receptor) research. This will help the company to increase its North America presence.

The company has presence in North America and Europe. The company has various subsidiaries that are Eurofins Agro science services Pty Ltd., Eurofins Agro science testing Pty Ltd., Eurofins Agro science services Ltd a., Eurofins Belgium NV, Eurofins Environment Testing Canada Inc., and among others.


Labcorp Drug Development headquartered in Burlington, North Caroline in USA was founded in year 1995. The company is engaged in products in Clinical laboratory business, end-to-end drug development, medical device and companion diagnostic, development solutions from early stage research to clinical development and commercial market access.– that help lead healthier lives.

  • In December 2019, LABCORP completed the acquisition of Toxikon Corporation. The addition of Toxikon to Labcorp Drug development boost Labcorp's strong expanding nonclinical development testing capabilities for pharmaceutical, biotech clients and creates a strategic footprint in drug development.

The company has wide North America presence across the world as North America, Europe, Latin America, Africa, Asia Pacific with its various subsidiaries such as Litholink (Chicago), Esoterix Genetic Laboratories LLC (USA), MedTox (USA), Pathology Associates Medical Laboratories (PAML) (USA) among others.


Charles River headquartered in Wilmington, MA was founded in year 1947. The company is engaged in products in drug discovery, medical devices, Pharmaceuticals and Biotechnology industries– that help lead healthier lives.

  • In October 2020, Charles River Laboratories International and ATEM Structural Discovery (ATEM) announced the formation of a strategic partnership to provide clients access to ATEM’s cryo-electron microscopy (cryo-EM) service solutions. Cryo-EM is a technique that determines the 3D structures of proteins and is utilized to identify how proteins function, how they malfunction in disease, and the most effective way to target them with therapies. This will enhance the service portfolio of the company.
  • In May2019, Charles River Laboratories International announced that it had signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. This will enhance the company’s North America presence.

The company has wide North America presence across the world as U.S, U.K, India and Australia with its subsidiaries such as HemaCare and Cellero are wholly owned subsidiaries.